Author/Authors :
Mohagheghi Darehranj, Samaneh Digestive Disease Research Center - Digestive Disease Research Institute - Tehran University of Medical Sciences, Tehran, Iran , Alatab, Sudabeh Digestive Disease Research Center - Digestive Disease Research Institute - Tehran University of Medical Sciences, Tehran, Iran , Vahedi, Homayoon Digestive Disease Research Center - Digestive Disease Research Institute - Tehran University of Medical Sciences, Tehran, Iran , Sadeghi, Anahita Digestive Disease Research Center - Digestive Disease Research Institute - Tehran University of Medical Sciences, Tehran, Iran , Sima, Alireza Digestive Disease Research Center - Digestive Disease Research Institute - Tehran University of Medical Sciences, Tehran, Iran , Malekzadeh, Masoud Digestive Disease Research Center - Digestive Disease Research Institute - Tehran University of Medical Sciences, Tehran, Iran , Anoshiravani, Amir Digestive Disease Research Center - Digestive Disease Research Institute - Tehran University of Medical Sciences, Tehran, Iran , Fakheri, Hafez Gut and Liver Research Center - Mazandaran University of Medical Sciences, Sari, Iran , Ebrahimi Daryani, Nasser Department of Gastroenterology - Imam Khomeini Hospital - Tehran University of Medical Sciences, Tehran, Iran , Mousavi, Abdolhamid Gastroenterology Department - Hormozgan Medical School - Hormozgan University of Medical Sciences, Hormozgan, Bandar-Abbas, Iran , Mansour-Ghanaei, Fariborz Gastrointestinal and Liver Diseases Research Center - Guilan University of Medical Sciences (GUMS), Rasht, Iran , Zahedi, Mohammad Javad Digestive Research Center - Kerman University of Medical Sciences, Kerman, Iran , Malekzadeh, Reza Digestive Disease Research Center - Digestive Disease Research Institute - Tehran University of Medical Sciences, Tehran, Iran
Abstract :
BACKGROUND
The anti-TNF drugs are shown to be highly effective in treatment of patients with moderate-tosevere
inflammatory bowel disease (IBD). Here, we aimed to assess the efficacy and safety of anti-
TNF therapy at the national level.
METHODS
IBD patients aged 15 > years who received Infliximab and/or CinnoRA® between 2013 to July
2018 were identified. The data extracted from medical dossier and telephonic interview. The efficacy
of therapy was defined as time to drug discontinuation or need for IBD-related surgery. The safety
was assessed based on patient’s reported adverse events.
RESULTS
We included 315 patients. The mean age of patients was 37.2 years and 62.2% of them developed
the disease before age 30 years. Involvement of masculoskeletal system was reported in 7.3% of
patients. Partial and complete response to Anti-TNF therapy was seen in 67% of patients. About
16% of patients did not respond to induction therapy and 16.9% of patients lost their response to
Anti-TNF during one year. No serious adverse events, serious opportunistic infection, tuberculosis
and malignancies reported by patients. Two patients reported pneumonia.
CONCLUSION
This study for the first time in our country, provides the evidences for efficacy of anti-TNF therapy
in moderate to severe IBD patients.
